Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12970739 | 1.00 | MDM2 (1.00) | MDM2TP53 | |
| SCHEMBL10299798 | 1.00 | MDM2 (1.00) | MDM2TP53 | |
| SCHEMBL1956097 | 1.00 | MDM2 (1.00) | MDM2TP53 | |
| SCHEMBL222983 | 1.00 | MDM2 (1.00) | MDM2TP53 | |
| SCHEMBL19866394 | 1.00 | MDM2 (1.00) | MDM2TP53 | |
| SCHEMBL29383972 | 1.00 | MDM2 (1.00) | MDM2TP53 | |
| SCHEMBL17533380 | 0.94 | MDM2 (1.00) | MDM2TP53 | |
| SCHEMBL221083 | 0.94 | MDM2 (0.89) | MDM2TP53 | |
| SCHEMBL1959036 | 0.94 | MDM2 (0.89) | MDM2TP53 | |
| SCHEMBL17249764 | 0.94 | MDM2 (1.00) | MDM2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250134877-A1 | METHODS OF TREATING CANCER DEPENDENT ON MYC GENE EXPRESSSION | KARTOS THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250134876-A1 | METHODS OF TREATING A CANCER OVEREXPRESSING ONE OR MORE BCL-2 FAMILY PROTEINS | KARTOS THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250090517-A1 | Methods of Treating Cancer | KARTOS THERAPEUTICS INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-12115153-B2 | Methods of treating cancer | KARTOS THERAPEUTICS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| EP-4398903-A1 | METHODS OF TREATING CANCER DEPENDENT ON MYC GENE EXPRESSION | Kartos Therapeutics (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-4398905-A1 | METHODS OF TREATING A CANCER OVEREXPRESSING ONE OR MORE BCL-2 FAMILY PROTEINS | Kartos Therapeutics (US) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024124240-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2019183523-A1 | HETERO-BIFUNCTIONAL DEGRADER COMPOUNDS AND THEIR USE AS MODULATORS OF TARGETED UBIQUINATION (VHL) | GENENTECH, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20190209700-A1 | SPIROCYCLIC INDOLONE POLYETHYLENE GLYCOL CARBONATE COMPOUND, COMPOSITION, PREPARATION METHOD AND USE THEREOF | JIANGSU YAYO BIOTECHNOLOGY CO. LTD. (CN) | 2019-07-11 | — | — | US | disclosed |
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-8088815-B2 | Spiroindolinone pyrrolidines | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088815-B2 | Spiroindolinone pyrrolidines | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088815-B2 | Spiroindolinone pyrrolidines | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011067185-A1 | SPIROINDOLINONE PYRROLIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | BARTKOVITZ DAVID JOSEPH | 2011-06-02 | — | — | US | disclosed |
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | BARTKOVITZ DAVID JOSEPH | 2011-06-02 | — | — | US | disclosed |
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | BARTKOVITZ DAVID JOSEPH | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | JAK2, JAK1, MPL | MDM2 52/4885TP53 25/4885 |
| US-12115153-B2 | Methods of treating cancer | VHL, MDM2, TP53 | MDM2 2/4885TP53 3/4885 |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | MDM2 2109/4885TP53 335/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | MDM2 23/4885TP53 2/4885 |
| US-20250134876-A1 | METHODS OF TREATING A CANCER OVEREXPRESSING ONE OR MORE BCL-2 FAMILY PROTEINS | BCL2, BCL2L2, BCL2L1 | MDM2 18/4885TP53 5/4885 |
| US-20250090517-A1 | Methods of Treating Cancer | VHL, MDM2, TP53 | MDM2 2/4885TP53 3/4885 |
| US-20250134877-A1 | METHODS OF TREATING CANCER DEPENDENT ON MYC GENE EXPRESSSION | MYC, MYCBP, TP53 | MDM2 6/4885TP53 3/4885 |
| US-20190209700-A1 | SPIROCYCLIC INDOLONE POLYETHYLENE GLYCOL CARBONATE COMPOUND, COMPOSITION, PREPARATION METHOD AND USE THEREOF | SI, HSD17B7, MKI67 | MDM2 621/4885TP53 43/4885 |
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | RPS4Y1, RB1, RPS4X | MDM2 1419/4885TP53 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.